---
title: Celltex Therapeutics Secures FDA Approval for Phase II Trials
description: Celltex Therapeutics Secures FDA Approval for Phase II Trials
---

[News ](https://www.yourway.com/news)

# [Celltex Therapeutics Secures FDA Approval for Phase II Trials](https://www.yourway.com/news/celltex-therapeutics-secures-fda-approval-for-phase-ii-trials)

 Written by [Yourway](https://www.yourway.com/news/author/yourway) | July 10, 2020

Celltex Therapeutics has secured [approval](https://www.clinicaltrialsarena.com/news/celltext-fda-nod-phaseii-trial/) from the U.S. Food and Drug Administration to move forward with their treatment for COVID-19, which involves autologous adipose tissue-derived mesenchymal stem cells (AdMSCs). These AdMSCs will be evaluated for efficacy in a multi-center, randomized, double-blind, placebo-controlled phase II trial. In order to ease the burden on patients, Yourway offers direct-to-patient (DTP) clinical trials, which do not require travel. This direct and efficient way of conducting trials has also been available throughout the pandemic.

[View full post](https://www.yourway.com/news/celltex-therapeutics-secures-fda-approval-for-phase-ii-trials)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Yourway"
  },
  "dateModified" : "2020-07-10T09:00:00.353Z",
  "datePublished" : "2020-07-10T09:00:00Z",
  "headline" : "Celltex Therapeutics Secures FDA Approval for Phase II Trials",
  "image" : {
    "@type" : "ImageObject",
    "height" : 5504,
    "url" : "https://f.hubspotusercontent30.net/hubfs/5402331/iStock-1224871551.jpg",
    "width" : 8256
  },
  "mainEntityOfPage" : "https://www.yourway.com/news/celltex-therapeutics-secures-fda-approval-for-phase-ii-trials",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News"
  }
}
```